Innate Pharma (France) Performance
| IPH Stock | EUR 1.88 0.01 0.53% |
The company retains a Market Volatility (i.e., Beta) of 0.26, which attests to not very significant fluctuations relative to the market. As returns on the market increase, Innate Pharma's returns are expected to increase less than the market. However, during the bear market, the loss of holding Innate Pharma is expected to be smaller as well. At this point, Innate Pharma has a negative expected return of -0.0076%. Please make sure to check out Innate Pharma's maximum drawdown, daily balance of power, relative strength index, as well as the relationship between the skewness and day typical price , to decide if Innate Pharma performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Innate Pharma has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong technical indicators, Innate Pharma is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors. ...more
| Begin Period Cash Flow | 136.8 M | |
| Total Cashflows From Investing Activities | -917 K |
Innate |
Innate Pharma Relative Risk vs. Return Landscape
If you would invest 193.00 in Innate Pharma on December 21, 2024 and sell it today you would lose (5.00) from holding Innate Pharma or give up 2.59% of portfolio value over 90 days. Innate Pharma is producing return of less than zero assuming 2.7131% volatility of returns over the 90 days investment horizon. Simply put, 24% of all stocks have less volatile historical return distribution than Innate Pharma, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Innate Pharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Innate Pharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Innate Pharma, and traders can use it to determine the average amount a Innate Pharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0028
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | IPH |
Estimated Market Risk
| 2.71 actual daily | 24 76% of assets are more volatile |
Expected Return
| -0.01 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| 0.0 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Innate Pharma is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Innate Pharma by adding Innate Pharma to a well-diversified portfolio.
Innate Pharma Fundamentals Growth
Innate Stock prices reflect investors' perceptions of the future prospects and financial health of Innate Pharma, and Innate Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Innate Stock performance.
| Return On Equity | -0.17 | |||
| Return On Asset | -0.043 | |||
| Profit Margin | (0.40) % | |||
| Operating Margin | (0.33) % | |||
| Current Valuation | 86.87 M | |||
| Shares Outstanding | 80.2 M | |||
| Price To Earning | 125.20 X | |||
| Price To Book | 1.43 X | |||
| Price To Sales | 3.04 X | |||
| Revenue | 12.11 M | |||
| EBITDA | (47.9 M) | |||
| Cash And Equivalents | 103.76 M | |||
| Cash Per Share | 2.62 X | |||
| Total Debt | 46.5 M | |||
| Debt To Equity | 2.70 % | |||
| Book Value Per Share | 1.46 X | |||
| Cash Flow From Operations | (58.46 M) | |||
| Earnings Per Share | (0.27) X | |||
| Total Asset | 267.5 M | |||
| Retained Earnings | (7 M) | |||
| Current Asset | 252 M | |||
| Current Liabilities | 60 M | |||
About Innate Pharma Performance
By analyzing Innate Pharma's fundamental ratios, stakeholders can gain valuable insights into Innate Pharma's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Innate Pharma has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Innate Pharma has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Innate Pharma S.A., a clinical-stage biotechnology company, discovers and develops therapeutic antibodies for the treatment of cancer in France and internationally. The company was founded in 1999 and is based in Marseille, France. INNATE PHARMA operates under Biotechnology classification in France and is traded on Paris Stock Exchange. It employs 191 people.Things to note about Innate Pharma performance evaluation
Checking the ongoing alerts about Innate Pharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Innate Pharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Innate Pharma generated a negative expected return over the last 90 days | |
| Innate Pharma may become a speculative penny stock | |
| The company reported the revenue of 12.11 M. Net Loss for the year was (52.81 M) with loss before overhead, payroll, taxes, and interest of (22.3 M). | |
| Innate Pharma has accumulated about 103.76 M in cash with (58.46 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.62, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 23.0% of the company shares are held by company insiders |
- Analyzing Innate Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Innate Pharma's stock is overvalued or undervalued compared to its peers.
- Examining Innate Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Innate Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Innate Pharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Innate Pharma's stock. These opinions can provide insight into Innate Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Innate Stock analysis
When running Innate Pharma's price analysis, check to measure Innate Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Innate Pharma is operating at the current time. Most of Innate Pharma's value examination focuses on studying past and present price action to predict the probability of Innate Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Innate Pharma's price. Additionally, you may evaluate how the addition of Innate Pharma to your portfolios can decrease your overall portfolio volatility.
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios |